Acurx Pharmaceuticals, Inc. (ACXP)
| Market Cap | 7.59M -1.7% |
| Revenue (ttm) | n/a |
| Net Income | -7.51M |
| EPS | -2.78 |
| Shares Out | 5.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 69,739 |
| Open | 1.470 |
| Previous Close | 1.460 |
| Day's Range | 1.420 - 1.470 |
| 52-Week Range | 1.310 - 8.340 |
| Beta | -2.03 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+1,072.41%) |
| Earnings Date | Aug 14, 2026 |
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ACXP stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 1,072.41% from the latest price.
News
Acurx announces FDA conditional approval of CIFBEZY as brand name for ibezapolst
Acurx (ACXP) Pharmaceuticals announced that the FDA has conditionally accepted the proposed proprietary, or brand name, CIFBEZY for ibezapolstat, the Company’s lead antibiotic product candidate being ...
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis ...
Acurx receives patents for DNA Polymerase IIIC inhibitors in Mexico and Japan
Acurx (ACXP) Pharmaceuticals announced that the Japan Patent Office and the Mexico Patent Office, respectively, have each granted a new patent which covers Acurx’s DNA Polymerase IIIC inhibitors inclu...
Acurx Pharmaceuticals Earnings Call Transcript: Q2 2026
FDA conditionally accepted a single phase III trial as pivotal for NDA, with PATHFINDER fully funded and set to start in Q4 2026. Cash increased to $10.7M, and new patents and partnerships support pipeline progress. Ongoing efforts target funding for broader phase III trials.
Acurx Pharmaceuticals Quarterly report: Q2 2026
Acurx Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 14, 2026.
Acurx Pharmaceuticals Earnings release: Q2 2026
Acurx Pharmaceuticals released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics f...
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
STATEN ISLAND, N.Y., Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecul...
Acurx partners with Leiden University Medical Center to develop its antibiotics
Acurx (ACXP) Pharmaceuticals announced a new scientific partnership with Leiden University Medical Center, or LUMC, in the Netherlands. Prior work under the November 2025 research grant from Health-Ho...
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and Acurx This prior wor...
Acurx announces outcome of meeting with FDA on ibezapolstat’s clinical program
Acurx (ACXP) Pharmaceuticals announced the successful outcome of a Type C Meeting conducted with FDA on July 13 to discuss ibezapolstat’s Phase 3 clinical program and scope of its planned…
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
Acurx has received FDA guidance in meeting minutes from a July 13, 2026 Type C Meeting to discuss ibezapolstat's (IBZ) Phase 3 clinical program, including the potential to submit an NDA (New Drug Appl...
Acurx’s ibezapolstat shows microbe preservation efficacy
Acurx (ACXP) Pharmaceuticals announced a poster presentation presented by Kevin Garey, University of Houston College of Pharmacy, Principal Investigator for microbiology at the 18th Biennial Congress ...
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
Data demonstrated beneficial bacterial taxa persist in fecal samples from patients with rCDI despite multiple prior CDI treatments with the antibiotic standards of care, vancomycin (VAN) and/or fidaxo...
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., July 8, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics fo...
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Results are from Acurx's ongoing scientific collaboration with Leiden University Medical Center (LUMC) partially under a grant from Health Holland to further study the mechanism of action of DNA pol I...
Acurx Pharmaceuticals Earnings Call Transcript: Q1 2026
Initiated a pivotal rCDI trial for ibezapolstat, leveraging strong phase II results and new FDA guidance that may allow single pivotal trials. Cash position improved to $9.3M, with reduced expenses and new capital raised to fund ongoing clinical programs.
Acurx Pharmaceuticals Quarterly report: Q1 2026
Acurx Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Acurx Pharmaceuticals Earnings release: Q1 2026
Acurx Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics fo...
Acurx files to sell 1.65M shares of common stock for holders
16:17 EDT Acurx (ACXP) files to sell 1.65M shares of common stock for holders
Acurx files to sell 1.3M shares of common stock for holders
16:18 EDT Acurx (ACXP) files to sell 1.3M shares of common stock for holders
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
DNA pol IIIC inhibitors demonstrate the unexpected benefit of gut microbiome preservation while demonstrating systemic antibacterial activity Neutropenic CD-1 mice were infected intramuscularly with m...
Acurx Pharmaceuticals Registration statement: Registration filing
Acurx Pharmaceuticals filed a registration statement on May 4, 2026, providing details about a securities offering with the SEC.
Acurx Pharmaceuticals Registration statement: Registration filing
Acurx Pharmaceuticals filed a registration statement on May 4, 2026, providing details about a securities offering with the SEC.